Skye Bioscience, Inc. Q3 2025 Earnings Recap

SKYE Q3 2025 November 11, 2025

Get alerts when SKYE reports next quarter

Skye Bioscience, Inc. delivered promising data from its Phase 2a CBEYOND study, demonstrating strong efficacy of Nimazumab in combination with semaglutide and reporting a net loss of $12.8 million for Q3 2025.

Earnings Per Share Beat

$-0.32 vs $-0.33 est.

+3.0% surprise

Market Reaction

1-Day +2.82%

5-Day -8.45%

30-Day -15.49%

See SKYE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Cash reserves stood at $35.3 million, expected to fund operations through 2027.
R&D expenses rose to $9.4 million, reflecting increased clinical trial activity and manufacturing costs.
Positive findings from the CBEYOND study revealed a 30% improvement in weight loss efficacy when combining Nimazumab with semaglutide.
Data also demonstrated enhanced metabolic benefits and safety with no significant adverse effects observed.
Enrollment in a 26-week extension study was completed, with results anticipated by late Q1 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SKYE on AllInvestView.